Drug updated on 5/3/2024
| Dosage Form | Capsule (oral; 2.3 mg, 3 mg, 4 mg) |
| Drug Class | Proteasome inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Summary
- Ixazomib (Ninlaro) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- A total of 11 systematic reviews/meta-analyses were reviewed to gather information about ixazomib's safety and effectiveness.
- When combined with lenalidomide and dexamethasone, ixazomib shows a longer progression-free survival than treatments like Rd alone or bortezomib monotherapy but falls short when compared to daratumumab combinations.
- In terms of overall survival rate, this drug outperforms certain other therapies including bortezomib alone; however, carfilzomib-, daratumumab-, and isatuximab-based treatments showed better response rates according to SUCRA analysis.
- For specific populations such as those with cytogenetic abnormalities t(4;14) and amp1q21, ixazomib demonstrates significant benefits in managing multiple myeloma especially among high-risk patients who have previously undergone at least one therapy session.
- Adverse effects associated with this drug include higher incidences of grade 3-4 thrombocytopenia, neuropathy infections, gastrointestinal disorders but no significant correlation was found between its use and occurrence of new primary malignant tumors or neutropenia indicating manageable health risks within clinical settings.
- Compared to regimens involving proteasome inhibitors (PIs) & immunodulatory drugs (IMiDs), which are known for their adverse events profile such as secondary primary malignancies linked specifically to lenalidamide maintenance post-autologous transplantation - an event not significantly correlated with Ninlaro usage based on the data reviewed from these documents.
- Ixazomb offers considerable patient convenience due it being orally administered, despite showing competitive but sometimes lesser effectiveness compared to newer drugs like isatuximab and carfilzomib.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ninlaro (ixazomib) Prescribing Information. | 2024 | Takeda Pharmaceutical Company Limited., Cambridge, MA |